Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20